Avacta Group plc, a UK-based healthcare technology and consumables business, provides innovative and proprietary solutions to the life sciences/healthcare sector through two operating divisions:

Avacta Analytical provides high-end analytical instrumentation and services to the biopharmaceutical sector, expected to be a US$200bn revenue market by 2013 and the fastest growing part of the pharmaceutical industry. The Company’s technologies are aimed at reducing the risks and expense associated with biological drug development and thereby reducing the final cost of drugs to patients. The Company’s lead analytical instrument, Optim, is distributed through Pall Corporation in US and SE Asia, Isogen Life Sciences in Europe, Cold Spring Biotech Corp in China and Taiwan and DKSH in Japan. Avacta sells Optim directly in the UK.

Avacta Animal Health provides diagnostic products and services for the US$1.5bn global veterinary diagnostics market. Its aim is to equip veterinary professionals with high quality animal health and well-being information through point of care diagnostics and laboratory based testing. Avacta’s AX-1 point of care immunoassay system is aimed at providing the veterinarian with rapid blood test results in the clinic. The initial range of tests launched with the AX-1 relates to Avacta’s world leading allergy testing brand Sensitest®. Avacta is developing further assays for the AX-1 system to diagnose a range of diseases in companion animals. Longer term, these technologies will be transferred into the human clinical diagnostics market.

Avacta joined AIM in August 2006 and is based in Wetherby, England.

http://www.avacta.com/

15 Nov
finnCap
200.00
Corporate